A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence
Crossref DOI link: https://doi.org/10.1186/2051-1426-3-S2-P166
Published Online: 2015-11-04
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Weber, Jeffrey
Grob, Jean-Jaques
Margolin, Kim A
Ascierto, Paolo A
Sznol, Mario
Ott, Patrick A
Lejeune, Chantal
de Pril, Veerle
Ruisi, Mary M
Hodi, F Stephen
Article History
First Online: 4 November 2015